45 companies

Harmony Biosciences Holdings

Market Cap: US$2.1b

A commercial-stage pharmaceutical company, focuses on developing and commercializing therapies for patients with rare and other neurological diseases in the United States.

HRMY

US$37.93

7D

1.2%

1Y

0.5%

Global Industrial

Market Cap: US$1.3b

Through its subsidiaries, operates as an industrial distributor of various industrial and maintenance, repair, and operation (MRO) products in the United States and Canada.

GIC

US$32.84

7D

3.1%

1Y

35.9%

Applied Industrial Technologies

Market Cap: US$10.5b

Distributes industrial motion, power, control, and automation technology solutions in the United States, Canada, Mexico, Australia, New Zealand, Singapore, and Costa Rica.

AIT

US$283.73

7D

3.8%

1Y

8.1%

Pegasystems

Market Cap: US$7.1b

Develops, markets, licenses, hosts, and supports enterprise software in the United States, rest of the Americas, the United Kingdom, rest of Europe, the Middle East, Africa, and the Asia-Pacific.

PEGA

US$43.03

7D

7.9%

1Y

-16.7%

Vita Coco Company

Market Cap: US$3.3b

Develops, markets, and distributes coconut water products under the Vita Coco brand name in the United States, Canada, Europe, the Middle East, Africa, and the Asia Pacific.

COCO

US$56.56

7D

-1.7%

1Y

43.5%

Pinterest

Market Cap: US$13.6b

Operates as a visual search and discovery platform in the United States, Canada, Europe, and internationally.

PINS

US$20.33

7D

-2.1%

1Y

-48.6%

ResMed

Market Cap: US$40.2b

Develops, manufactures, distributes, and markets medical devices and cloud-based software applications to diagnose, treat, and manage respiratory disorders in the United States and internationally.

RMD

US$263.54

7D

4.8%

1Y

11.0%

Stride

Market Cap: US$3.7b

Provides proprietary and third-party online curriculum, software systems, and educational services in the United States and internationally.

LRN

US$88.11

7D

2.7%

1Y

-36.6%

ACADIA Pharmaceuticals

Market Cap: US$3.9b

A biopharmaceutical company, focuses on the development and commercialization of medicines for central nervous system (CNS) disorders and rare diseases in the United States.

ACAD

US$22.70

7D

-8.3%

1Y

22.8%

Page 2 of 2